We are committed to building sustainable relationships across the scientific and business community that help us combine transformative advances in the understanding of human disease with the science of therapeutics to dramatically advance human health.

Collaboration Defines Our Culture

Vertex realizes that collaborating with the world’s experts is a cornerstone to solving some of science’s most difficult problems. It defines our culture.

Externally, our collaborations with companies, academia, research organizations and nonprofit organizations help drive scientific innovation and the development of new medicines.
Internally, it creates an environment that encourages the open exchange of ideas and provides the freedom for our talented employees to explore new scientific concepts. Our Vertex Opportunities for Intrapreneurship & Corporate Evolution (VOICE) program is a great example.

Focus & Priorities
Our goal is to create transformative medicines for people with serious diseases with a high unmet medical need. To support this mission, we seek external partnerships that promote scientific innovation. We believe that innovation should not be limited to opportunities based on specific stages of development or particular treatment modalities, but instead, focused on creating relationships that are grounded in deep biological knowledge of the disease and target. Current priorities include:

Supporting our cystic fibrosis strategy of bringing the best medicines to patients through accessing external assets that complement our existing research efforts and clinical assets.
Diversifying our portfolio with transformative medicines in diseases with a high unmet need.
Leveraging cutting-edge technology platforms to accelerate the discovery of new disease targets, compounds, delivery mechanisms and treatment modalities.
Maximizing the potential of our internal assets by using strategic collaborations and licensing opportunities to enable speedy and thorough development.

Areas of Interest
We welcome inquiries about establishing new collaborations involving both preclinical and development-stage assets, as well as drug discovery and development technologies. We are actively exploring all approaches that may change the treatment of a serious disease where no adequate treatment currently exists. In addition to cystic fibrosis, the following are diseases of further research interest:

Alpha-1 Antitrypsin (AAT) deficiency
Sickle Cell Disease and Beta Thalassemia
Pain
APOL1-Mediated Kidney Disease

We are also seeking platform technologies that will enable exploration of new diseases or disease targets.

Partner of Choice

At Vertex, we value developing mutually beneficial strategic relationships. Our approach is to create successful partnerships with well-articulated deal principles and value propositions. Our portfolio of alliances consists of a variety of collaboration models to meet different needs of our partners.

Our Alliance Management function works to maximize the value of the collaboration across both organizations. We view our strategic partnerships as a key component of our overall corporate strategy. As a result, we are empowered to advocate for the needs of our partners with continued focus on the alignment of our common goals. Alliance Management creates a seamless and efficient decision-making process by providing access to key decision-makers. This fosters an environment of open and continuous communication between Vertex and its partners to ensure success in meeting our goals. We are continually evaluating our procedures and processes to improve outcomes for our partners.

Vertex -Model VX-561 -Potential Small Molecule Medicines